ArticleBMC public health2026
Medications for opioid use disorder, recovery supports, and overdose risk -- a database linkage study of a rural cohort of people who inject drugs and use opioids.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMedications for opioid use disorder (MOUD) are the gold standard treatment for opioid use disorder, but rural-dwelling people who inject drugs (PWID) may have lower access. PWID may also receive outpatient or residential treatments, attend mutual help groups, or reside in recovery housing. We aimed to investigate which supports were associated with time to first fatal or nonfatal opioid-involved overdose in a cohort of PWID who used opioids in the past 30 days.
methodsPWID who used opioids (N = 751) in the past 30 days were recruited in Wisconsin using respondent-driven sampling and completed a cross-sectional survey in 2018-2019. Fatal and nonfatal opioid-involved overdose incidence was estimated through 2022 via linkage with vital records, emergency department, and hospitalization data. Cox proportional hazards models summarized associations of reporting MOUD, outpatient counseling, residential treatment, mutual help group participation, and living in recovery housing in the 30 days before enrollment with time to first fatal/nonfatal opioid overdose adjusted for sociodemographic characteristics, health insurance, drug use frequency, substance use severity, criminal legal system involvement, and overdose history. Self-reported barriers to MOUD were summarized among those who had never used each MOUD.
resultsApproximately 18.1% (N = 136) used MOUD, 22.0% (N = 165) had outpatient counseling, 7.2% (N = 54) had residential treatment, 19.7% (N = 148) participated in mutual help, and 7.2% (N = 54) lived in recovery housing in the 30 days before enrollment. During follow-up, 10.7% of participants experienced ≥ 1 opioid-involved overdose, including 114 nonfatal overdoses (incidence: 3,291.6 per 100,000 person-years) and 26 fatal overdoses (incidence: 784.5 per 100,000 person-years). Past 30-day MOUD was associated with a 78% reduction in risk of future opioid-involved fatal/nonfatal overdose (95% CI: 0.08, 0.57). Past 30-day counseling, residential treatment, mutual help, and recovery housing were not associated with fatal/nonfatal overdose. The top barrier to MOUD reported was being unable to afford MOUD (reported among 33.2% who never used buprenorphine, 27.7% who never used methadone, 22.7% who never used naltrexone).
conclusionsRecent MOUD was highly protective against experiencing fatal or nonfatal overdose in a cohort of PWID who used opioids in the past 30 days, reinforcing the need for widespread MOUD access in rural communities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.